Načítá se...
Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?
Patients with blood disorders (including leukaemia, platelet function disorders and coagulation factor deficiencies) or acute bleeding receive blood-derived products, such as red blood cells, platelet concentrates and plasma-derived products. Although the risk of pathogen contamination of blood prod...
Uloženo v:
| Vydáno v: | Ann Hematol |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer Berlin Heidelberg
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5486800/ https://ncbi.nlm.nih.gov/pubmed/28624906 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-017-3028-4 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|